MedWatch

A part of Watch Media

GN Hearing's CEO regards new OTC regulation positively

The framework for the future over-the-counter sales channel in the US extends beyond what CEO Gitte Aabo had anticipated. Overall, she is pleasantly surprised.

Photo: GN Store Nord / PR
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN

The framework of the upcoming US sales channel for over-the-counter (OTC) hearing aids was recently made public, and the big hearing aid manufacturers have been reading the over 100-page document from the US Food and Drug Administration carefully.

So far, CEO at GN Hearing Gitte Aabo's opinion is positive, she explains.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

  1. Top news from MedWatch this week
  2. Hearing firms urge FDA to increase OTC safety requirements
  3. Danish bank cuts Genmab price target, retains "buy" recommendation
  4. Audientes ships first hearing aid batch to India
  5. Coloplast initiates trial of ostomy leakage product
  6. Novo Nordisk launches oral semaglutide in India
  7. Zealand Pharma finds all patients for phase III study
  8. Leo Pharma's Boston boss exits company
  9. Danish bank expects slow start to 2022 for Coloplast, lowers price target
  10. Swedish bank slashes Novo Nordisk price target ahead of 2022 outlook
  11. Overwhelming majority passes new EMA powers
  12. Hearing aid industry association responds to FDA's proposed OTC regulation
  13. Leo Pharma ends Boston bet
  14. WSA merges with its independent retailer
  15. Layoffs and restructuring will prepare Leo Pharma for IPO

Jobs

See all jobs

See all jobs